Inozyme Pharma

Focus: Inozyme Pharma is a rare disease-focused biotech company specializing in enzyme replacement therapy, headquartered in Boston with a pipeline concentrated on ultra-rare metabolic disorders.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Inozyme Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Inozyme Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

No Intervention for this observational study

Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

N/A

Clinical Trials (1)

NCT05050669Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency

N/A

Help build intelligence for Inozyme Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead development of INZ-701, which spans Phase 1-3 trials across multiple rare disease indications (ENPP1 deficiency, calciphylaxis, ABCC6 deficiency), offering exposure to multi-indication drug development
Specialized enzyme replacement therapy platform positions you in a high-barrier-to-entry therapeutic area with limited competition
Rare disease focus enables deep clinical expertise development and potential for accelerated regulatory pathways (orphan drug designations)

Watch Out For

Zero active job openings currently listed, suggesting minimal near-term hiring or potential organizational constraints
Pre-revenue biotech status with missing financial data (funding, cash position, employee count) raises questions about runway and capital adequacy

Generated by Claude from Inozyme Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

No Intervention for this observational study

Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency

N/A

Clinical Trials (1)

NCT06302439PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency

N/A

Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency

Generalized Arterial Calcification in Infancy

N/A

Clinical Trials (1)

NCT04372446Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency

N/A

INZ-701

Calciphylaxis

Phase 1

Clinical Trials (1)

NCT06283589The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis

Phase 1

INZ-701

Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

Phase 1/2

Clinical Trials (1)

NCT04686175Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency

Phase 1/2

INZ-701

Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

Phase 2

Clinical Trials (1)

NCT06739980The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency

Phase 2

INZ-701

Gene Mutations

Phase 2

Clinical Trials (1)

NCT06462547ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

Phase 2

INZ-701

Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency

Phase 3

Clinical Trials (1)

NCT06046820The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 8 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo